Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Grows By 300.2%

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 680,800 shares, an increase of 300.2% from the December 31st total of 170,100 shares. Based on an average trading volume of 348,300 shares, the short-interest ratio is presently 2.0 days. Currently, 1.0% of the company’s shares are short sold.

Hedge Funds Weigh In On Tiziana Life Sciences

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC increased its position in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,387 shares of the company’s stock after purchasing an additional 13,500 shares during the period. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent quarter.

Tiziana Life Sciences Trading Down 2.5 %

TLSA traded down $0.02 on Wednesday, hitting $0.69. The company had a trading volume of 222,115 shares, compared to its average volume of 1,297,624. The business’s fifty day simple moving average is $0.84 and its 200 day simple moving average is $0.94. Tiziana Life Sciences has a 12-month low of $0.41 and a 12-month high of $1.74.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.